Back |
home / stock / vyne / vyne message board
Subject | By | Source | When |
---|---|---|---|
Just now noticed that $VYNE gained 21% over | jugs | investorshub | 09/19/2020 4:07:29 PM |
We closed on Friday a week ago at | jugs | investorshub | 09/18/2020 6:04:43 PM |
Beautiful | artfulife | investorshub | 09/16/2020 10:02:36 PM |
I'm grateful that I get to work with them. | SpockJones | investorshub | 09/16/2020 8:17:03 PM |
Now down $8K for me. | jugs | investorshub | 09/16/2020 3:24:14 PM |
Down 3 g's | pickspicks1 | investorshub | 09/16/2020 3:16:48 PM |
For a moment this morning I was actually | jugs | investorshub | 09/16/2020 3:11:45 PM |
Rolling along slow and steady | pickspicks1 | investorshub | 09/16/2020 2:37:58 PM |
Those aren't question marks at the end of | artfulife | investorshub | 09/15/2020 11:07:08 PM |
Amazing. Im sure you and your coworkers make | artfulife | investorshub | 09/15/2020 9:50:52 PM |
Thank you for going the extra mile. Much | jugs | investorshub | 09/15/2020 8:24:24 PM |
sorry - maybe this will flow thru properly | Billr05 | investorshub | 09/15/2020 8:16:44 PM |
No numerical target points? | jugs | investorshub | 09/15/2020 7:42:09 PM |
not the best cut and paste from my | Billr05 | investorshub | 09/15/2020 6:40:20 PM |
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter Phase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo and will evaluate VYN201 gel in 1%, 2% and 3% concentrations compared t...
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD trial expected to start this quarter BRIDGEWATER, N.J., May 0...
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage ...